Manuel Hidalgo
Manuel Hidalgo
Weill Cornell Medicine
Verified email at
Cited by
Cited by
Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine
DD Von Hoff, T Ervin, FP Arena, EG Chiorean, J Infante, M Moore, T Seay, ...
New England Journal of Medicine 369 (18), 1691-1703, 2013
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses
S Jones, X Zhang, DW Parsons, JCH Lin, RJ Leary, P Angenendt, ...
science 321 (5897), 1801-1806, 2008
Pancreatic cancer
M Hidalgo
New England Journal of Medicine 362 (17), 1605-1617, 2010
A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development
A Jimeno, G Feldmann, A Suárez-Gauthier, Z Rasheed, A Solomon, ...
Molecular cancer therapeutics 8 (2), 310-314, 2009
Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations
DM Hyman, I Puzanov, V Subbiah, JE Faris, I Chau, JY Blay, J Wolf, ...
New England Journal of Medicine 373 (8), 726-736, 2015
Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab
S Khambata-Ford, CR Garrett, NJ Meropol, M Basik, CT Harbison, S Wu, ...
Journal of clinical oncology 25 (22), 3230-3237, 2007
Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies
M Hidalgo, LL Siu, J Nemunaitis, J Rizzo, LA Hammond, C Takimoto, ...
Journal of clinical oncology 19 (13), 3267-3279, 2001
Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma
MB Atkins, M Hidalgo, WM Stadler, TF Logan, JP Dutcher, GR Hudes, ...
Journal of clinical oncology 22 (5), 909-918, 2004
Patient-derived xenograft models: an emerging platform for translational cancer research
M Hidalgo, F Amant, AV Biankin, E Budinská, AT Byrne, C Caldas, ...
Cancer discovery 4 (9), 998-1013, 2014
Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial
DD Von Hoff, RK Ramanathan, MJ Borad, DA Laheru, LS Smith, TE Wood, ...
Journal of Clinical Oncology 29 (34), 4548, 2011
Development of matrix metalloproteinase inhibitors in cancer therapy
M Hidalgo, SG Eckhardt
Journal of the National Cancer Institute 93 (3), 178-193, 2001
DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer
CA Iacobuzio-Donahue, B Fu, S Yachida, M Luo, H Abe, CM Henderson, ...
Journal of clinical oncology 27 (11), 1806, 2009
Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of …
D Soulieres, NN Senzer, EE Vokes, M Hidalgo, SS Agarwala, LL Siu
Journal of clinical oncology 22 (1), 77-85, 2004
Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study
E Galanis, JC Buckner, MJ Maurer, JI Kreisberg, K Ballman, J Boni, ...
Journal of Clinical Oncology 23 (23), 5294-5304, 2005
The rapamycin-sensitive signal transduction pathway as a target for cancer therapy
M Hidalgo, EK Rowinsky
Oncogene 19 (56), 6680-6686, 2000
Developing inhibitors of the epidermal growth factor receptor for cancer treatment
V Grunwald, M Hidalgo
Journal of the National Cancer Institute 95 (12), 851-867, 2003
Pancreatic cancer: from state-of-the-art treatments to promising novel therapies
I Garrido-Laguna, M Hidalgo
Nature reviews Clinical oncology 12 (6), 319-334, 2015
Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity
LA DeGraffenried, WE Friedrichs, DH Russell, EJ Donzis, AK Middleton, ...
Clinical cancer research 10 (23), 8059-8067, 2004
Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma
ZA Rasheed, J Yang, Q Wang, J Kowalski, I Freed, C Murter, SM Hong, ...
Journal of the National Cancer Institute 102 (5), 340-351, 2010
An in vivo platform for translational drug development in pancreatic cancer
B Rubio-Viqueira, A Jimeno, G Cusatis, X Zhang, C Iacobuzio-Donahue, ...
Clinical cancer research 12 (15), 4652-4661, 2006
The system can't perform the operation now. Try again later.
Articles 1–20